Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

teva pharma b.v. - pramipexole dihydrochloride monohydrate - parkinson disease - anti-parkinson drugs - pramipexole teva is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).pramipexole teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate; sucrose - azacitidine-teva is indicated for the treatment of patients with: intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukemia [cmmol (10 percent-29 percent marrow blasts without myeloproliferative disorder)], acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

teva pharma b.v.  - budesonide, formoterol fumarate dihydrate - asthma; pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.copdsymptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev1) 

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

teva gmbh - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressants - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Israel - Inggeris - Ministry of Health

teva israel ltd - spironolactone - tablets - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

Israel - Inggeris - Ministry of Health

teva pharmaceutical industries ltd, israel - epinephrine - solution for injection - epinephrine 1 mg/ml - epinephrine - epinephrine - adrenaline teva solution for injection is indicated in the following situations:– spasm of the airways in acute asthma attacks.– rapid relief of allergic reactions to drugs or other substances.– emergency treatment of anaphylactic shock.– cardiac arrest and cardiopulmonary resuscitation (physical measures should be used first).

Israel - Inggeris - Ministry of Health

teva israel ltd - gefitinib - film coated tablets - gefitinib 250 mg - gefitinib - gefitinib teva is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.

Israel - Inggeris - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).

Israel - Inggeris - Ministry of Health

teva israel ltd - olanzapine - tablets orodispersible - olanzapine 10 mg - olanzapine - acute and maintenance treatment of schizophrenia. olanza odt teva is indicated for the management of the manifestations of psychotic disorders.olanza odt teva is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment olanza odt teva is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanza odt teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israel - Inggeris - Ministry of Health

teva israel ltd - olanzapine - tablets orodispersible - olanzapine 5 mg - olanzapine - acute and maintenance treatment of schizophrenia. olanza odt teva is indicated for the management of the manifestations of psychotic disorders.olanza odt teva is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment olanza odt teva is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanza odt teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.